SGX:H02Pharmaceuticals
Haw Par (SGX:H02) Valuation Check After Profitability Rises On Full Year Results
Earnings snapshot and why it matters
Haw Par (SGX:H02) released its full year 2025 results with sales of S$229.97 million versus S$244.82 million a year earlier, while net income reached S$265.46 million and basic EPS came in at S$1.199.
See our latest analysis for Haw Par.
The latest earnings release comes after a mixed year for the share price, with a 1 day share price return of 1.38% to S$15.45, a 30 day share price return decline of 9.28% and a 1 year total shareholder return of 33.25%...